1589561186372COR3002OpenA Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior ChemotherapyNCT06750094IndustrialAdultTreatmentColonChen, KevinMedStar Health and GUMC; Medstar Franklin Square Medical CenterGastrointestinalOncology GroupMHRI Oncology Baltimore2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>